Pancreatic Cancer Research

ResearcherOregon Health & Science UniversityActive in the last 2 years

Terry K. Morgan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0742-5012; OpenAlex author ID A5009699749. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
63
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 7 papers · 2026: 1 paper

Papers 19

  1. Liquid Biopsy Differentiation of Pancreatic Cancer From Non-Cancerous Pancreatic Disease Using Dielectrophoresis-Recovered Nanoparticles Carrying Cell-Free DNA… Co-author DOI 10.1002/smll.202502532↗
  2. Protocol to purify and culture human pancreatic cancer cells from patient-derived xenografts. Co-author DOI 10.1016/j.xpro.2025.103672↗
  3. Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients. Co-author DOI 10.1038/s41467-025-62685-y↗
  4. Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. Co-author DOI 10.1038/s43018-024-00881-3↗
  5. Self-amplifying NRF2-EZH2 epigenetic loop converts KRAS-initiated progenitors to invasive pancreatic cancer. Co-author DOI 10.1038/s43018-025-01003-3↗
  6. Author Correction: Autotaxin-lysolipid signaling suppresses a CCL11-eosinophil axis to promote pancreatic cancer progression. Co-author DOI 10.1038/s43018-025-01035-9↗
  7. Long Noncoding RNAs Preserve Pancreatic Cancer Identity and Resist Cell Fate Conversion Co-author DOI 10.1101/2025.06.25.661419↗
  8. Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse model Co-author DOI 10.1101/2025.07.14.664767↗
  9. Sendai virus is robust and consistent in delivering genes into human pancreatic cancer cells. Co-author DOI 10.1016/j.heliyon.2024.e27221↗
  10. Autotaxin-lysolipid signaling suppresses a CCL11-eosinophil axis to promote pancreatic cancer progression. Co-author DOI 10.1038/s43018-023-00703-y↗
  11. Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity. Co-author DOI 10.1093/narcan/zcad016↗
  12. Longitudinal Analysis of Human Pancreatic Adenocarcinoma Development Reveals Transient Gene Expression Signatures. Co-author DOI 10.1158/1541-7786.mcr-21-0483↗
  13. Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po.20.00287↗
  14. MyD88 signalling is critical in the development of pancreatic cancer cachexia. Co-author DOI 10.1002/jcsm.12377↗
  15. The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Co-author DOI 10.1038/s41467-019-12657-w↗
  16. Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Co-author DOI 10.1038/s41467-019-13151-z↗
  17. Establishment and characterization of a novel murine model of pancreatic cancer cachexia. Co-author DOI 10.1002/jcsm.12225↗
  18. Human pancreatic cancer fusion 2 (HPC2) 1-B3: a novel monoclonal antibody to screen for pancreatic ductal dysplasia. Co-author DOI 10.1002/cncy.21223↗
  19. The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma. First author DOI 10.1016/j.humpath.2011.11.012↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rosalie C. Sears · 10 shared papers, 2021–2026 · strength 1.80
  2. Jason M. Link · 5 shared papers, 2021–2025 · strength 0.88
  3. Brett C. Sheppard · 6 shared papers, 2012–2025 · strength 0.83
  4. Dmytro Grygoryev · 4 shared papers, 2021–2025 · strength 0.74
  5. Jungsun Kim · 4 shared papers, 2021–2025 · strength 0.74
  6. Lisa M. Coussens · 5 shared papers, 2019–2025 · strength 0.60
  7. Brittany L. Allen-Petersen · 3 shared papers, 2024–2025 · strength 0.58
  8. Jonathan Robert Brody · 3 shared papers, 2023–2025 · strength 0.50
  9. Motoyuki Tsuda · 3 shared papers, 2025 · strength 0.49
  10. Sohinee Bhattacharyya · 2 shared papers, 2024–2025 · strength 0.45
  11. Holly Sandborg · 2 shared papers, 2024–2025 · strength 0.45
  12. Mara H. Sherman · 2 shared papers, 2024–2025 · strength 0.45
  13. Luis Francisco Diaz · 2 shared papers, 2024–2025 · strength 0.45
  14. Katherine R. Pelz · 4 shared papers, 2019–2025 · strength 0.43
  15. Julien Tessier · 2 shared papers, 2025 · strength 0.41
  16. Gordon Brent Mills · 2 shared papers, 2025 · strength 0.37
  17. Thuy T. M. Ngo · 2 shared papers, 2021–2025 · strength 0.35
  18. Kevin G. Burfeind · 4 shared papers, 2017–2019 · strength 0.34
  19. Katherine A. Michaelis · 4 shared papers, 2017–2019 · strength 0.34
  20. Xinxia Zhu · 4 shared papers, 2017–2019 · strength 0.34
  21. Daniel L. Marks · 4 shared papers, 2017–2019 · strength 0.34
  22. Patrick Joseph Worth · 2 shared papers, 2025 · strength 0.33
  23. Isabel A. English · 2 shared papers, 2025 · strength 0.33
  24. Kevin Hawthorne · 2 shared papers, 2025 · strength 0.33
  25. Ellen M. Langer · 2 shared papers, 2025 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.